Boston Scientific Corporation disclosed a material cybersecurity incident that began on August 25, 2026, causing global operational disruptions including network outages that impaired manufacturing capabilities and the processing of customer orders. Although unauthorized access has not been identified as ongoing and major distribution centers have resumed shipping at normal levels, the company determined the incident will likely have a material impact on its third quarter and full-year 2026 results of operations. Consequently, Boston Scientific expects to miss its previously provided net sales growth and adjusted EPS guidance ranges for these periods. The company anticipates recovering some impacted revenue as it reduces backlogs but stated that full impacts remain unknown. Boston Scientific operates in the medical device industry, developing and manufacturing products for interventional and specialty medical procedures.

Boston Scientific reported second quarter 2026 net sales of $5.442 billion, a 7.5% increase on a reported basis and 7.0% on an operational basis compared to the prior year period. GAAP net income attributable to common stockholders was $907 million, or $0.61 per share, while adjusted EPS reached $0.86, beating the guidance range of $0.82 to $0.84. The company completed a previously announced $2 billion accelerated share repurchase program, acquiring approximately 40 million shares. Additionally, Boston Scientific invested $1.5 billion in MiRus LLC for an approximate 34% equity stake and exclusive option to acquire the MiRus TAVR business. Management raised full-year 2026 adjusted EPS guidance to $3.28–$3.32 and third-quarter net sales growth guidance to 3–5%. Boston Scientific is a global medical technology company that develops, manufactures, and sells minimally invasive interventional medical devices.

Boston Scientific Corporation entered into an investment agreement with MiRus LLC, acquiring a 33.75% non-voting equity interest for $1.5 billion in cash, following a $100 million payment previously made. The deal also includes an exclusive call option to acquire 100% of MiRus's TAVR-related assets for up to $3.0 billion in additional cash, contingent upon the achievement of specific clinical and regulatory milestones.

Boston Scientific Corporation has entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank, National Association, as part of its previously announced $5 billion share repurchase authorization. The transaction is expected to be completed by June 30, 2026, leaving $3 billion remaining under the company's repurchase program.

Boston Scientific Corporation's 2026 Annual Meeting resulted in the election of 10 directors and the approval of charter amendments to eliminate supermajority voting provisions and provide for officer exculpation. Shareholders also approved an increase in shares for the Employee Stock Purchase Plan but rejected a proposal that would have allowed stockholders owning at least 25% of common stock to call special meetings.